<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="35664">Statins</z:chebi> (3-hydroxy-3-methylglutaryl <z:chebi fb="3" ids="15346">coenzyme A</z:chebi> reductase inhibitors) reduce cardiovascular risk through mechanisms that might affect the development of <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: To evaluate whether <z:chebi fb="0" ids="35664">statin</z:chebi> use is associated with a lower risk of <z:hpo ids='HP_0000726'>dementia</z:hpo> compared with never use of <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering agents (LLAs) </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN: Cohort study of community-dwelling adults 65 years and older </plain></SENT>
<SENT sid="3" pm="."><plain>The analysis included 2798 participants free of <z:hpo ids='HP_0000726'>dementia</z:hpo> at baseline </plain></SENT>
<SENT sid="4" pm="."><plain>MAIN OUTCOME MEASURES: Using Cox proportional hazards regression analysis, we estimated the risk of incident <z:hpo ids='HP_0000001'>all</z:hpo>-cause and type-specific <z:hpo ids='HP_0000726'>dementia</z:hpo> associated with time-dependent <z:chebi fb="0" ids="35664">statin</z:chebi> therapy compared with never use of LLAs </plain></SENT>
<SENT sid="5" pm="."><plain>The primary analyses incorporated a 1-year lag between exposure and outcome </plain></SENT>
<SENT sid="6" pm="."><plain>Secondary analyses included the final year of exposure and modeled <z:chebi fb="0" ids="35664">statin</z:chebi> use as current use vs nonuse to simulate a case-control approach </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Compared with never use of LLAs, ever use of <z:chebi fb="0" ids="35664">statins</z:chebi> was not associated with the risk of <z:hpo ids='HP_0000001'>all</z:hpo>-cause <z:hpo ids='HP_0000726'>dementia</z:hpo> (multivariable-adjusted hazard ratio [HR], 1.08; 95% confidence interval [CI], 0.77-1.52), <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> alone (HR, 1.21; 95% CI, 0.76-1.91), mixed <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (HR, 0.87; 95% CI, 0.44-1.72), or vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> alone (HR, 1.36; 95% CI, 0.61-3.06) </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, in secondary analyses, current use of <z:chebi fb="0" ids="35664">statins</z:chebi> compared with nonuse of LLAs was associated with HRs of 0.69 (95% CI, 0.46-1.02) for <z:hpo ids='HP_0000001'>all</z:hpo>-cause <z:hpo ids='HP_0000726'>dementia</z:hpo> and 0.56 (95% CI, 0.35-0.92) for any <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In this cohort study, <z:chebi fb="0" ids="35664">statin</z:chebi> therapy was not associated with a decreased risk of <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Methodological differences may explain why results of this cohort investigation differ from those of prior case-control studies </plain></SENT>
<SENT sid="11" pm="."><plain>Additional investigation is needed to determine whether and for whom <z:chebi fb="0" ids="35664">statin</z:chebi> use may affect <z:hpo ids='HP_0000726'>dementia</z:hpo> risk </plain></SENT>
</text></document>